Extrawell Pharmaceutical Holdings Limited (HKG:0858)

HKG:0858 Balance Sheet

Financials in millions HKD. Fiscal year is April - March.

Assets

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Cash & Equivalents	89.51	77.77	93.61	102.4	111.88
Short-Term Investments	1.77	-	-	0.75	0.74
Trading Asset Securities	103.48	917.09	0.66	1.75	1.91
Cash & Short-Term Investments	194.75	994.86	94.27	104.91	114.52
Cash Growth	-80.42%	955.32%	-10.14%	-8.40%	-11.39%
Accounts Receivable	7.09	7.8	4.22	5.8	7.81
Other Receivables	9.79	33.14	34.98	36.51	36.28
Receivables	18.46	40.94	52.63	47.49	44.09
Inventory	4.89	4.74	7.27	3.02	8.47
Prepaid Expenses	-	1.14	1.13	2.54	1.4
Other Current Assets	21.17	21.11	22.15	20.71	25.91
Total Current Assets	239.28	1,063	177.44	178.66	194.38
Property, Plant & Equipment	123.69	119.78	126.04	136.54	148.39
Long-Term Investments	213.26	311.93	974.81	1,110	955.27
Goodwill	1.81	1.81	1.81	1.81	1.81
Long-Term Deferred Tax Assets	0.07	0.07	0.07	0.07	0.07
Other Long-Term Assets	2.15	2.28	2.42	2.55	2.68
Total Assets	587.34	1,526	1,287	1,445	1,317

Liabilities

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Accounts Payable	3.96	4.43	4.66	6.63	6.46
Accrued Expenses	23.03	17.7	19.7	21.49	24.08
Current Portion of Leases	1.17	1.9	1.38	1.32	2.19
Current Income Taxes Payable	11.31	19	18.1	16.43	17.2
Current Unearned Revenue	0.12	3.16	5.36	6.61	6.87
Other Current Liabilities	-	2.31	2.18	4.53	7.26
Total Current Liabilities	39.59	48.5	51.37	57.01	64.06
Long-Term Debt	165.05	139.04	117.12	98.62	83.07
Long-Term Leases	3.11	-	1.91	3.29	0.04
Long-Term Unearned Revenue	4.12	4.01	4.17	4.38	5
Total Liabilities	211.87	191.55	174.58	163.3	152.18

Shareholders' Equity

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Common Stock	25.5	23.9	23.9	23.9	23.9
Additional Paid-In Capital	-	196.58	196.58	196.58	196.58
Retained Earnings	-	670.69	448.04	610.99	481.73
Comprehensive Income & Other	349.59	443.38	444.61	450.25	463.45
Total Common Equity	375.09	1,335	1,113	1,282	1,166
Minority Interest	0.38	0.26	-0.51	-0.15	-0.73
Shareholders' Equity	375.47	1,335	1,113	1,282	1,165
Total Liabilities & Equity	587.34	1,526	1,287	1,445	1,317

Additional Metrics

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Total Debt	169.33	140.94	120.41	103.22	85.31
Net Cash (Debt)	25.42	853.92	-26.14	1.68	29.22
Net Cash Growth	-97.02%	-	-	-94.24%	-47.23%
Net Cash Per Share	0.01	0.26	-0.01	0.00	0.01
Filing Date Shares Outstanding	2,550	2,390	2,390	2,390	2,390
Total Common Shares Outstanding	2,550	2,390	2,390	2,390	2,390
Working Capital	199.69	1,014	126.07	121.65	130.32
Book Value Per Share	0.15	0.56	0.47	0.54	0.49
Tangible Book Value	373.29	1,333	1,111	1,280	1,164
Tangible Book Value Per Share	0.15	0.56	0.46	0.54	0.49
Buildings	-	118.88	120.17	122.84	136.49
Machinery	-	62.02	61.42	55.61	52.77
Construction In Progress	-	0.46	0.09	6.01	7.89

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

Aug 1, 2026

Data Sources Report a data error